Innovative Solutions
to Acute and Chronic Illnesses
Occidiofungin The Fungus Killer
A New Treatment Option for Serious Fungal Infections
For decades, recurrent vulvovaginal candidasis (RVVC) has been a poorly managed disease and has been a neglected infectious disease leaving over 100 million women worldwide with ineffective treatment options.
​
Thanks to years of groundbreaking research, our lead asset is poised to provide a first-in-class solution to not only this disease, but will potentially alleviate the burden of drug resistance in the treatment of oral, dermal, and invasive fungal infections.
Mutacin
Providing Solutions to Antibiotic Resistance in Bacteria
Prevalence of antibiotic resistant bacteria has been increasing at the same time as the rate of antibiotic discovery has been declining. With our second asset we are a part of a resurgence in antibiotic discovery, providing a new solution to systemic bacterial infections, including those caused by MRSA. With this therapeutic compound, we can reduce mortality and morbidity associated with many emerging antibiotic resistant infections.
Sano Chemicals by the Numbers
$8
Million dollars raised
7
Indications under development
11
Patents
22
Personnel, Advisors and Directors